Log in for full access to this activity, if you are registered.

Registration Options

Activity Dates: 06/13/2016 - 04/18/2019

Target Audience

This course is designed for pharmacists, nurse practitioners or other healthcare professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.

Session Summary

New medications and mechanisms for the treatment of depression have come into the picture in the past 3-5 years. For many years, serotonergic drugs have been the treatment of choice for major depressive disorder. With the exception of bupropion and mirtazapine, the most common mechanism of action for antidepressants has been to inhibit the reuptake of serotonin. The STAR*D trial and other similar studies have repeatedly shown the remission rate for antidepressants to be approximately 30%, which has led to questions about whether the current antidepressants on the market are targeting depression via the most effective mechanism. As a result, new serotonergic antidepressants are being developed, and medications with non-serotonergic mechanisms are being studied in depression. As new medications are developed, practitioners must determine how to fit them into their practice. Providers need information about the advantages and disadvantages of each medication and the data that supports their use with emphasis on how to identify specific patients who might benefit from these new medications based on their demographics, treatment history and symptom profile.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date. (login first)
  • Complete the evaluation at the end of the activity. (login first)
  • If necessary, complete the post-test retest no later than the closing activity date. (login first)
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)

This course is provided online at cpnp.org and consists of the speaker audio and slides. A PDF file of the slides is also provided and access is available to participants indefinitely although ACPE credit is available only through the course expiration date.

Participants in this course must complete an examination and achieve a score of 70% or greater. Successful completion of the course also requires the completion of a course evaluation. ACPE statements of credit can be retrieved by participants online at cpnp.org immediately upon successful completion of the course.

Faculty Information and Disclosures

Learning Objectives

  1. Predict time to response and remission based on knowledge about novel antidepressant mechanisms.
  2. Analyze the results of clinical trials focused on the use of new medications for the treatment of depression.
  3. Evaluate the place in therapy of novel antidepressants for treatment of depression utilizing a patient case.

Continuing Education Credit and Disclosures

Activity Dates: 06/13/2016 - 04/18/2019
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-16-002-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 1.0 contact hours (0.1 CEUs) of knowledge-based continuing education credit from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-0000-16-002-H01-P (1.0 contact hours).